Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir
Alosaimi et al.,
Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving..,
Pharmaceuticals, doi:10.3390/ph15121456
Retrospective 200 hospitalized COVID-19 patients in Saudi Arabia, showing no significant difference in outcomes between HCQ and favipiravir.
risk of death, 400.0% higher, RR 5.00, p = 0.49, treatment 2 of 37 (5.4%), control 0 of 37 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), propensity score matching.
|
hospitalization time, 42.9% lower, relative time 0.57, p = 0.63, treatment 37, control 37, propensity score matching.
|
time to discharge, 28.6% lower, relative time 0.71, p = 0.74, treatment 37, control 37, propensity score matching.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Alosaimi et al., 24 Nov 2022, retrospective, Saudi Arabia, peer-reviewed, 13 authors, study period April 2020 - March 2021, this trial compares with another treatment - results may be better when compared to placebo.
Contact:
w.alturaiki@mu.edu.sa (corresponding author).
Abstract: pharmaceuticals
Article
Analyzing the Difference in the Length of Stay (LOS) in
Moderate to Severe COVID-19 Patients Receiving
Hydroxychloroquine or Favipiravir
Bandar Alosaimi 1 , Huda M. Alshanbari 2 , Muath Alturaiqy 3 , Halah Z. AlRawi 1 , Saad Alamri 1 ,
Asma Albujaidy 4 , Aljawharah Bin Sabaan 5 , Ahmed A. Alrashed 6 , Ahmad Alamer 7,8 , Fayez Alghofaili 9 ,
Khaled Al-Duraymih 10 , Abdulaziz J. Alshalani 11 and Wael Alturaiki 9, *
1
2
3
4
5
6
7
8
9
Citation: Alosaimi, B.; Alshanbari,
10
H.M.; Alturaiqy, M.; AlRawi, H.Z.;
Alamri, S.; Albujaidy, A.; Bin Sabaan,
A.; Alrashed, A.A.; Alamer, A.;
11
*
Research Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh 11525, Saudi Arabia
Department of Mathematical Sciences, College of Science, Princess Nourah bint Abdulrahman University,
Riyadh 11671, Saudi Arabia
Department of Internal Medicine, Alzulfi General Hospital, Riyadh Second Health Cluster,
Riyadh 11525, Saudi Arabia
Department of Clinical Pharmacy Service, Prince Mohammed bin Abdulaziz Hospital, Riyadh Second Health
Cluster, Riyadh 11525, Saudi Arabia
Pharmacy College, Almaarifa University, Riyadh 11597, Saudi Arabia
Department of Pharmaceutical Services, Main Hospital, King Fahad Medical City, Riyadh Second Health
Cluster, Riyadh 11525, Saudi Arabia
Department of Clinical Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj 11942, Saudi Arabia
Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona,
Tucson, AZ 85721, USA
Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University,
Majmaah 11952, Saudi Arabia
Main Laboratory and Blood Bank, Alzulfi General Hospital, Riyadh Second Health Cluster,
Riyadh 11525, Saudi Arabia
Alzulfi General Hospital, Riyadh Second Health Cluster, Riyadh 11525, Saudi Arabia
Correspondence: w.alturaiki@mu.edu.sa
Alghofaili, F.; et al. Analyzing the
Difference in the Length of Stay (LOS)
in Moderate to Severe COVID-19
Patients Receiving
Hydroxychloroquine or Favipiravir.
Pharmaceuticals 2022, 15, 1456.
https://doi.org/10.3390/ph15121456
Academic Editor: Marco Fiore
Received: 14 October 2022
Accepted: 18 November 2022
Published: 24 November 2022
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affiliations.
Copyright: © 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
Abstract: Background: The coronavirus 2019 (COVID-19) disease, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus led to a global pandemic. HCQ and FPV were
used early in the pandemic as a treatment modality for COVID-19. Various studies evaluated the
HCQ and FPV effectiveness, based on the mortality endpoint and showed conflicting results. We
hypothesize that analyzing the difference in the LOS as a significant endpoint would be of a major
interest, especially for healthcare providers, to prevent a lengthy hospitalization and disease progression. Methods: This is a retrospective observational study, conducted via a medical chart review of
COVD-19 patients who were admitted between April 2020 and March 2021 with a moderate to severe
illness. The LOS endpoint was tested using the paired Wilcoxon signed-rank (WSR) model. Prior to
using the WSR model, the balance..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit